CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial

NCT ID: NCT03716934

Last Updated: 2025-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-27

Study Completion Date

2022-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, randomized, multicenter study comparing the relative efficacy and safety of cryoablation of PVs using the Arctic Front Advance® balloon catheter with antiarrhythmic therapy in patients with persistent AF.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ablation of pulmonary veins is a very effective treatment for the treatment of paroxysmal atrial fibrillation. The benefit of the isolation of pulmonary veins in persistent atrial fibrillation seems to be minor and the level of scientific evidence available requires additional clinical trials to define the value of ablation in this type of patients.

The symptomatology of atrial fibrillation recurrences is variable among patients and among differens moments in the same patient. Pharmacological treatment and ablation have been used to reduce the symptomatology of atrial fibrillation recurrences and to increase the proportion of asymptomatic recurrences. Different forms of electrical monitoring of the heart rate are used to evaluate the effectiveness of an intervention. Frequents monitoring periods provide the information of the heart rate and the effect of any intervention.

The "Confirm RX heart monitor® (Abbott)" is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function. This implantable Holter automatically detects and saves atrial and ventricular arrhythmic episodes. The device can be analyzed in person or remotely, and can help to make decisions regarding anticoagulant and antiarrhythmic treatment of patients, while representing a powerful research tool for evaluate the effectiveness of different therapeutic options.

This is a prospective, randomized, multicenter study that compares the relative efficacy and safety of cryoablation of pulmonary veins using the Arctic Front Advance® balloon catheter with antiarrhythmic treatment in patients with persistent atrial fibrilation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cryoablation

Cryoablation for bidirectional block of all pulmonary veins

Group Type EXPERIMENTAL

Arctic Front Advance® balloon catheter

Intervention Type DEVICE

Cryoablation of bidirectional block of all pulmonary veins

Confirm RX heart monitor® (Abbott)

Intervention Type DEVICE

Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function

Antiarrythmics

The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.

Group Type ACTIVE_COMPARATOR

Antiarrhythmic drug

Intervention Type DRUG

The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.

Confirm RX heart monitor® (Abbott)

Intervention Type DEVICE

Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arctic Front Advance® balloon catheter

Cryoablation of bidirectional block of all pulmonary veins

Intervention Type DEVICE

Antiarrhythmic drug

The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.

Intervention Type DRUG

Confirm RX heart monitor® (Abbott)

Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Class I or III

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with recurrent persistent atrial fibrilation

Exclusion Criteria

* Patients with atrial fibrilation for more than one year at baseline
* Atrial fibrilation prior ablation
* Age\> 75 years or \<18 years
* Hyperthyroidism
* Hypertrophic cardiomyopathy
* Severe valvular disease (stenosis or regurgitation)
* Carriers of cardiac valves
* Anteroposterior diameter of left atrium\> 50 mm (left parasternal long axis)
* Contraindications for anticoagulation
* Left atrial thrombus
* Anemia
* Active infection
* Pregnancy
* Atrial fibrilation secondary to transient, avoidable or correctable causes (hyperthyroidism, pneumonia, pulmonary embolism, drugs, hydroelectrolytic alterations ...)
* Life expectancy of less than 24 months
* Participation in another non-purely observational study
* Patients unable to understand treatment and / or study and / or providing adequate informed consent
* Any condition, that in the opinion of the physician responsible for the patient, contraindicates any of the treatments of the study
* Microalbuminemia
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital San Carlos, Madrid

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nicasio Perez Castellano

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundacion para Investigación Biomedica Hospital Clinico San Carlos

Madrid, Madrid, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17/507-R_M

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

STOP Persistent AF
NCT03012841 COMPLETED NA